Key result
Alirocumab cuts Lp(a) levels by ~30% versus placebo.
Why the study?
Lipoprotein(a) is an independent cardiovascular risk factor with limited treatment options, necessitating evaluation of alirocumab's effect on Lp(a) levels.
Does alirocumab 150 mg Q2W reduce Lp(a) concentrations in patients with hypercholesterolemia on background lipid-lowering therapy?
RCT (n=185)
double-blind
randomized
Does alirocumab 150 mg Q2W reduce Lp(a) concentrations in patients with hypercholesterolemia on background lipid-lowering therapy?
Alirocumab 150 mg every 2 weeks significantly reduces Lp(a) levels in patients with hypercholesterolemia, with reductions largely independent of LDL-C lowering.
Answers are grounded in this paper and cite their sources.
Supports alirocumab 150 mg Q2W for Lp(a) lowering in hypercholesterolemia; confirms effect largely independent of LDL-C in meta-analysis.
Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease, with limited treatment options. This analysis evaluated the effect of a monoclonal antibody to proprotein convertase subtilisin/kexin 9, alirocumab 150 mg every 2 weeks (Q2W), on Lp(a) levels in pooled data from 3 double-blind, randomized, placebo-controlled, phase 2 studies of 8 or 12 weeks' duration conducted in patients with hypercholesterolemia on background lipid-lowering therapy (NCT01266876, NCT01288469, and NCT01288443). Data were available for 102 of 108 patients who received alirocumab 150 mg Q2W and 74 of 77 patients who received placebo. Alirocumab resulted in a significant reduction in Lp(a) from baseline compared with placebo (-30.3% vs -0.3%, p <0.0001). Median percentage Lp(a) reductions in the alirocumab group were of a similar magnitude across a range of baseline Lp(a) levels, resulting in greater absolute reductions in Lp(a) in patients with higher baseline levels. Regression analysis indicated that <5% of the variance in the reduction of Lp(a) was explained by the effect of alirocumab on low-density lipoprotein cholesterol. In conclusion, pooled data from 3 phase 2 trials demonstrate substantive reduction in Lp(a) with alirocumab 150 mg Q2W, including patients with baseline Lp(a) >50 mg/dl. Reductions in Lp(a) only weakly correlated with the magnitude of low-density lipoprotein cholesterol lowering.
No takes yet. Share an insight, caveat, or question.
Gaudet et al. (2014) conducted an RCT in hypercholesterolemia (n=185). alirocumab vs. placebo was evaluated on reduction in Lipoprotein(a) from baseline (p=<0.0001). Alirocumab every 2 weeks reduced Lipoprotein(a) levels from baseline compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: